Abstract Details

Title Cerebral Small Vessel Disease is Associated With Motoric Cognitive Risk Syndrome in Older Adults

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P4 - Poster Session 4 (5:00 PM-6:00 PM)

Poster/Presentation
Number 3-001

Objective To explore the association between imaging markers of CSVD and MCR and its key clinical components.

Background Cerebral small vessel disease (CSVD) is a heterogeneous group of vascular pathology associated with poor outcomes in aging. Markers of CSVD include white matter hyperintensities (WMHs) and lacunes. Motoric cognitive risk syndrome (MCR) is characterized by subjective cognitive complaints and slow gait. MCR confers higher risk of dementia, including vascular dementia (VD) and shares risk factors with CSVD.

Design/Methods We analyzed cross-sectional data from cohorts of community-dwelling older adults without dementia spanning 4 countries (n=1772). WMHs and lacunes were quantified manually using fluid attenuated inverse recovery (FLAIR)/T1 MRI sequences. Logistic and linear regression models evaluated the associations between WMH and lacunes and outcomes of interest; MCR, gait speed, and cognitive complaints.

Results The mean age of our combined cohort was 71.1, 49.9% of our cohort were women, 7.3% met criteria for MCR. Higher frontal and basal ganglia WMH scores were associated with MCR (OR=1.23, p=0.007, OR=1.31, p=0.023, respectively). Lacunes in the basal ganglia were associated with MCR (OR=1.57, p=0.018). Higher WMH scores in the frontal, parietal, and temporal regions were associated with slower gait speed (β=-1.48 cm/s, p<0.001, β=-0.77 cm/s, p=0.041, β=-1.57 cm/s, p=0.021), respectively. Higher WMH scores in temporal regions and basal ganglia were associated with cognitive complaints (OR=1.15, p=0.042, OR=1.18, p=0.015).

Conclusions

In this multi-national cohort study of older adults, overall burden and regional patterns of WMH and lacunes were independently associated with MCR and its individual components. The findings can guide future studies into vascular pathways leading to cognitive decline via MCR.

Authors/Disclosures
Juan P. Vázquez, MD PRESENTER	Dr. Vazquez has nothing to disclose.
Joe Verghese, MD, FAAN (Stony Brook University)	Dr. Verghese has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MedRhythms Inc. The institution of Dr. Verghese has received research support from National Institutes of Health.
Gilles Allali, MD, PhD	Dr. Allali has nothing to disclose.
Helena Blumen, PhD	Prof. Blumen has nothing to disclose.

��ɫ��

��ɫ��